

7 February 2014



ABN: 56 006 569 106

A: 108 Outram Street
West Perth, WA 6005

T: +61 (8) 9486 2333

F: +61 (8) 9355 4580

The Company Announcements Platform

ASX Limited

By E-lodgement

Transgene Announces Topline Preliminary Results from Phase 2b Part of TIME Trial with TG4010 in Non-Small Cell Lung Cancer

The Board of Virax Holdings Limited ("Virax" or "the Company") (ASX: **VHL**) would like to record the Company's position in relation to the recent announcement made by Transgene, dated 8 January 2014, on the results of the TG4010 trial for Non-Small Cell Lung Cancer (NSCLC), to shareholders.

As previously announced to the market, the Company licensed its Co-X-Gene™ technology to major French biotechnology company Transgene for use in two of Transgene's immunotherapeutic products; for the treatment for pathologies relating to human papilloma virus (HPV) infection that can lead to cervical cancer (*TG4001*), and for the treatment for non-small cell lung cancer (NSCLC) (*TG4010*).

Transgene has reported topline results from Phase 2B part of the TIME trial which was to evaluate the TG4010 MUC-1 targeted immunotherapy in combination with chemotherapy versus placebo plus chemotherapy in the first-line treatment of MUC-1 positive advanced NSCLC patients. The overall results warrant continuation into Phase 3 part of TIME study. (The complete details of the Transgene announcement and trial specifics can be found via Transgene's website <http://www.transgene.fr/>)

(Direct announcement link:

http://www.transgene.fr/index.php?option=com_press_release&task=download&id=244&l=en)

Since successful completion of the Phase 2B trial, Transgene has signed an exclusive option agreement with Novartis for the development and commercialization of TG4010 for the first-line treatment of NSCLC and other potential cancer indications.

Under the Company's licensing agreement with Transgene, there is the potential for the Company to receive licensing royalties from Transgene if the TG4010 immunotherapeutic product moves to commercialization. The Company will be closely following the progression of Transgene's Phase 3 trial on TG4010, and will continue to update shareholders on the Company's position in relation to the licensing agreement as they become available.

The Company is very excited with the strong results coming out of the Transgene's trials, which highlights the strength of the Company's Co-X-Gene™ technology and further potential surrounding its current IP portfolio.

Furthermore, the Company expects to receive the intellectual property report prepared by the independent expert in the coming weeks, for the purposes of assisting in the further development and exploitation of the Company's existing licensing arrangements, patents and IP portfolio.

The Company is confident that it can build on the experience with its Co-X-Gene™ technology and generate further licensing opportunities. The Board has also been approached by third parties to explore potential collaborative opportunities and on development of its current patent portfolio.

-Ends-

For further information contact:

Sean Henbury

Company Secretary

Ph: +61 (0) 8 9486 2333

Dr Wayne Millen

Executive Chairman

Ph: +61 (0) 8 9476 4555

About Virax

Virax is a biopharmaceutical company and is currently engaged in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer.

Virax has granted a licence to major French biotechnology company Transgene for access to Virax's Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products. These are: TG4001 – a treatment for pathologies relating to human papilloma virus (HPV) infection that can lead to cervical cancer, and TG4010 – a treatment for non-small cell lung cancer (NSCLC).

Additionally, Virax Developments Pty Ltd, a wholly owned subsidiary of Virax, is developing VIR201, a HIV/AIDS immunotherapeutic (therapeutic vaccine) that has been tested successfully in two clinical trials in Australia. Trials have also been conducted in South Africa with the support of a major mining consortium.

In addition to the above, the Board is actively seeking to expand its asset base with complimentary technology that will generate additional shareholder value.